{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:45:49Z","timestamp":1761741949923},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1995,7,1]],"date-time":"1995-07-01T00:00:00Z","timestamp":804556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer Part B: Oral Oncology"],"published-print":{"date-parts":[[1995,7]]},"DOI":"10.1016\/0964-1955(95)00019-e","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T15:50:27Z","timestamp":1027612227000},"page":"258-260","source":"Crossref","is-referenced-by-count":16,"title":["A database for mucositis induced by cancer chemotherapy"],"prefix":"10.1016","volume":"31","author":[{"given":"S.T.","family":"Sonis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.A.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/0964-1955(95)00019-E_BIB1","first-page":"11","article-title":"Prevention and management of oral mucositis induced by antineoplastic therapy","volume":"5","author":"Sonis","year":"1991","journal-title":"Oncology"},{"key":"10.1016\/0964-1955(95)00019-E_BIB2","first-page":"13","article-title":"Long-term, ambulatory, continuous iv infusion of 5-FU for the treatment of advanced adenocarcinomas","volume":"69","author":"Caballero","year":"1985","journal-title":"Cancer Treatment Reports"},{"key":"10.1016\/0964-1955(95)00019-E_BIB3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1985.3.4.485","article-title":"Remission induction of meningeal leukemia with high-dose intravenous methotrexate","volume":"3","author":"Balis","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/0964-1955(95)00019-E_BIB4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/1097-0142(19910715)68:2<248::AID-CNCR2820680205>3.0.CO;2-4","article-title":"Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer","volume":"68","author":"Roth","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/0964-1955(95)00019-E_BIB5","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood.V63.5.1102.1102","article-title":"An effective therapy for both undifferentiated (including Burkitt's) lymphoma and lymphoblastic lymphomas in children and young adults","volume":"63","author":"Magrath","year":"1984","journal-title":"Blood"},{"key":"10.1016\/0964-1955(95)00019-E_BIB6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.1986.tb01115.x","article-title":"A phase I\u2013II study of cytosine arabinoside, daunorubicin, and VP16\u2013213 in adult patients with acute non-lymphocytic leukemia","volume":"16","author":"Bishop","year":"1986","journal-title":"Aust NZ J Med"},{"key":"10.1016\/0964-1955(95)00019-E_BIB7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/BF00685897","article-title":"Acute mucocutaneous toxicity following high-dose hydroxyurea","volume":"32","author":"Brincker","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/0964-1955(95)00019-E_BIB8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/1097-0142(19910815)68:4<744::AID-CNCR2820680414>3.0.CO;2-R","article-title":"Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea","volume":"68","author":"Lokich","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/0964-1955(95)00019-E_BIB9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF01965262","article-title":"Oral manifestations and fever in immuno-compromised patients with haematological malignancies","volume":"8","author":"Bergmann","year":"1989","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/0964-1955(95)00019-E_BIB10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/00365549309169668","article-title":"Failure of clindamycin to influence the course of severe oromucositis associated with streptococcal bacteraemia in allogenic bone marrow transplant recipients","volume":"25","author":"Donnelly","year":"1993","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/0964-1955(95)00019-E_BIB11","first-page":"1","article-title":"CALGB Expanded Common Toxicity Criteria","author":"Brigham and Women's Hospital","year":"1991"},{"key":"10.1016\/0964-1955(95)00019-E_BIB12","first-page":"141","article-title":"Comprehensive criteria for accessing therapy-related toxicity","volume":"8","author":"Ajaini","year":"1990","journal-title":"Cancer Invest"},{"issue":"6","key":"10.1016\/0964-1955(95)00019-E_BIB13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00000421-198212000-00009","article-title":"PALA in advanced breast cancer. A Phase II pilot study by the ECOG","volume":"5","author":"Taylor","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"10.1016\/0964-1955(95)00019-E_BIB14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/0277-5379(85)90282-2","article-title":"EORTC Guidelines for Phase I Trials with Single Agents in Adults","volume":"21","year":"1985","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/0964-1955(95)00019-E_BIB15","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/1097-0142(19911201)68:11<2359::AID-CNCR2820681105>3.0.CO;2-A","article-title":"Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide","volume":"68","author":"Saphner","year":"1991","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/0964-1955(95)00019-E_BIB16","first-page":"99","article-title":"Phase II trial of spirogermanium in central nervous system tumors. A Southwest Oncology Group Study","volume":"71","author":"Goodwin","year":"1987","journal-title":"Cancer Treatment Reports"},{"key":"10.1016\/0964-1955(95)00019-E_BIB17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting the results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/0964-1955(95)00019-E_BIB18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/030089168807400113","article-title":"A Phase II study of 5-FU, teniposide, and mitomycin-C combination chemotherapy in advanced colorectal carcinomas","volume":"74","author":"Becouran","year":"1987","journal-title":"Tumori"},{"key":"10.1016\/0964-1955(95)00019-E_BIB19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00000421-198510000-00017","article-title":"Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man","volume":"8","author":"Byfield","year":"1985","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"10.1016\/0964-1955(95)00019-E_BIB20","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/0277-5379(91)90421-9","article-title":"Infusion of floxuridine plus etoposide plus cisplatin in human maligancies","volume":"27","author":"Lokich","year":"1991","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/0964-1955(95)00019-E_BIB21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.1985.3.3.326","article-title":"Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testes","volume":"3","author":"Logothetis","year":"1985","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/0964-1955(95)00019-E_BIB22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00000421-198708000-00016","article-title":"Combined mitoxantrone plus doxorubicin in the treatment of breast cancer","volume":"10","author":"Stewart","year":"1987","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/0964-1955(95)00019-E_BIB23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/1097-0142(19890815)64:4<793::AID-CNCR2820640404>3.0.CO;2-8","article-title":"5-Fluorouracil rechal-lenge by protracted infusion in refractory breast cancer","volume":"64","author":"Jabboury","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/0964-1955(95)00019-E_BIB24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00000421-198408000-00002","article-title":"Phase II evaluation of PALA in patients with refractory metastatic sarcomas","volume":"7","author":"Kuzrock","year":"1984","journal-title":"Am J Clin Oncol"}],"container-title":["European Journal of Cancer Part B: Oral Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:096419559500019E?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:096419559500019E?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T19:20:55Z","timestamp":1578684055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/096419559500019E"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1995,7]]}},"alternative-id":["096419559500019E"],"URL":"https:\/\/doi.org\/10.1016\/0964-1955(95)00019-e","relation":{},"ISSN":["0964-1955"],"issn-type":[{"value":"0964-1955","type":"print"}],"subject":[],"published":{"date-parts":[[1995,7]]}}}